4,901 trials
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects · Apathy
Primary: Determination of Maximum Plasma Concentration [Cmax] of IRL757 — 2.88; 11.42 μmol/L
Opioid Use Disorder · Chronic Pain
Primary: Retention — 3.7; 3.6 number of sessions attended
Healthy
Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
Shigella Infection · Enterotoxigenic Escherichia Coli Infection
Primary: Participants Experiencing Fever, Diarrhea, or Dysentery; Solicited Local Adverse Events; Solicited Systemic Adverse Events; and Clinical Safety Laboratory Adverse Events…
Mild Cognitive Impairment
Primary: Retention — 11; 15 Participants
Campylobacter Infection
Primary: Number and Percentage of Participants With Solicited Local Adverse Events (AEs) Through 7 Days After Each Study Vaccination — 4; 9; 2; 10 Participants
Health, Subjective
Primary: Incidence Rate of Drug Allergy Following ID Injection of the IP — 0; 0; 1; 0 Participants
Healthy
Primary: Plasma Concentration of Zavegepant at 30 Minutes Post-dose on Day 1 of Period 1- Tasso Device Versus (vs.) Standard Venous Phlebotomy — 16.50; 17.87; 2.843; 8.367…
Actinic Keratosis
Primary: AE — 3; 0; 2; 3 participants
Cardiovascular Disease
Primary: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) — 5; 3; 3; 5 Participants
Neoplasms
Primary: Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks) — 0; 0; 0 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Schizophrenia, Schizoaffective Disorder
Primary: Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation) — 39.26; 35.62; 29.68 nanograms (ng)/milliliter (mL)
Neoplasms · Carcinoma, Non-Small-Cell Lung
Primary: Dose Escalation: Maximum-tolerated Dose (MTD) of the BI 754111 Plus Ezabenlimab Combination — NA Milligram
Hepatic Impairment · Healthy
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV) — 152; 150; 215; 113 h*ng/mL